IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 2163 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed504    
    Printed14    
    Emailed0    
    PDF Downloaded30    
    Comments [Add]    

Recommend this journal

 

 DRUG WATCH
Year : 2021  |  Volume : 53  |  Issue : 3  |  Page : 229-233

The effects of empagliflozin on cardiometabolic risk factors in patients with type 2 diabetes: A short-term observational study


1 Department of Pharmacology, KMCH College of Pharmacology, Coimbatore, Tamil Nadu, India
2 Department of Diabetes and Endocrinology, Kovai Medical Center and Hospital, Coimbatore, Tamil Nadu, India
3 Department of Diabetes and Endocrinology, Kovai Medical Center and Hospital; KMCH Research Foundation, Coimbatore, Tamil Nadu, India

Correspondence Address:
Dr. Krishnan Swaminathan
Department of Diabetes and Endocrinology, Kovai Medical Center and Hospital, Coimbatore - 641 014, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijp.IJP_669_18

Rights and Permissions

The aim of this study was to assess the short-term cardiometabolic outcomes in type 2 diabetes patients receiving empagliflozin in a tertiary referral center. Three hundred and fifteen consecutive patients started on empagliflozin were followed for a 4-month period after local ethics committee approval for a range of outcomes. Data were recorded on Microsoft Excel and transposed to SPSS for further analysis. Empagliflozin treatment resulted in statistically significant reductions in weight, glycosylated hemoglobin, and systolic and diastolic blood pressures along with favorable lipid profile outcomes over a 4-month period. The rates of discontinuation of the medications due to genomycotic infections were extremely low at 0.6% with no episodes of severe hypoglycemia or euglycemic diabetic ketoacidosis. Empagliflozin therapy, either in addition to other oral agents or insulin, seems to result in favorable outcomes in cardiometabolic risk factors in the immediate short term. Long-term follow-up of this cohort will shed light on cardiovascular outcomes and adverse effects in our population in real-world clinical practice.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow